AGTX
Agentix Corp. [AGTX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
AGTX Stock Summary
Top 10 Correlated ETFs
AGTX
Top 10 Correlated Stocks
AGTX
In the News
AGTX Financial details
Company Rating
-
Market Cap
1.29M
Income
-1.53M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
14 Feb 2024
P/E
-0.81
Forward P/E
-
PEG
0.09
P/S
-
P/B
-0.47
P/C
-
P/FCF
-8.21
Quick Ratio
-
Current Ratio
0.11
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.04
EPS next Y
-
EPS next Q
-
EPS this Y
-91.03%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-78.07%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
13.33%
-
-
-
-
SMA20
25%
SMA50
150%
SMA100
25%
Inst Own
-
Inst Trans
-
ROA
-462%
ROE
73%
ROC
0.58%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.0301-0.129
52W High
-
52W Low
-
RSI
53.58
Rel Volume
23.32
Avg Volume
1.3K
Volume
30.2K
Perf Week
-4.43%
Perf Month
34.29%
Perf Quarter
-6%
Perf Half Y
-6%
-
-
-
-
Beta
-1.497
-
-
Volatility
0%, 0%
Prev Close
0%
Price
0.047
Change
-5.53%
Company Profile
- Volume Average 1.3K
- Market Capitalization 1.29M
- CEO Mr. Salman Hoda
- Headquarters Dana Point,CA,US
- IPO Date 2015-08-21
-
Website
https://www.agentixcorp.com 
Agentix Corp., a clinical development stage company, focuses on the development and commercialization of therapeutics to treat metabolic diseases. Its product pipeline includes AGTX-2004, a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, which has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver diseases. The company was formerly known as FairWind Energy, Inc. and changed its name to Agentix Corp. in June 2019. Agentix Corp. was incorporated in 2013 and is based in Dana Point, California.
